Takeda to invest €40m in Dublin operations expansion
pharmafile | December 5, 2016 | News story | Manufacturing and Production | Dublin, Ireland, Nanlarotm, Takeda
Takeda has announced it is to invest $40 million in a new facility in Dublin, adding a new facility and 40 new job vacancies to its Grange Castle site.
The expansion will include the addition of a new standalone high containment production facility for the sole purpose of manufacturing its oncology product Ninlarotm. The company originally set up operations in Ireland in 1997 and now employs over 400 staff across three sites in the region.
“We are delighted that Takeda has chosen Ireland for this investment and proud that we have been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide,” commented Paul Keogh, plant director at Takeda Ireland Grange Castle. “We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site.”
Minister for Jobs, Enterprise and Innovation Mitchell O’Connor also said of the announcement: “The pharma industry makes a huge contribution to the Irish economy in terms of jobs and exports, and is one of the fastest growing sectors. Takeda’s decision to manufacture their new cancer treatment in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here. I’m delighted that this investment will bring a further 40 jobs to the company’s existing Clondalkin facility.”
Matt Fellows
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
Takeda announces launch of Framework to help support patient access to life-extending combination treatments
The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help …
